WHO Trial Finds Remdesivir Has ‘No Meaningful Effect’ In COVID-19 Patients

Enlarge this image

Boxes containing vials of remdesivir at a pharmaceutical company in Giza, Egypt.

hide caption

toggle caption

Fadel Dawood/DPA/Picture Alliance via Getty Images

Live Updates: Trump Tests Positive For Coronavirus
Trump Is Taking Remdesivir. Here’s How It Works To Control The Coronavirus

The WHO panel says it’s possible there may be some benefit from the drug. But its relatively high cost along with the risks posed by giving it intravenously led them to recommend against using it.

The retail price of remdesivir in the U.S. was set by Gilead at $520 a dose. A typical treatment course requiring six or more doses costs thousands of dollars per patient. The drug is administered as an infusion in a medical setting and — ignoring the example of President Trump, who had a relatively mild case — it was only being used for hospitalized COVID-19 patients with severe forms of the disease.

On Thursday, Gilead issued a statement saying it is disappointed in the WHO’s decision. The pharmaceutical company and other advocates of remdesivir point to a National Institutes of Health study from April that showed the drug cut the recovery time for patients with severe cases of the disease by five days.

Emily Smith, a professor of public health at the Milken Institute School of Public Health at The George Washington University says the early studies did show a small benefit from remdesivir in some hospitalized patients. She says the various recommendations for or against remdesivir that have been issued by different regulatory bodies over the past few months aren’t inherently contradictory.

«While it might feel like people are disagreeing on what the evidence is, I actually see it as different conclusions based on different values,» Smith says.

«When WHO guidelines are made, it involves different values that are much broader than the things considered by the FDA, which weighs very heavily the clinical outcome data.»

Coronavirus Live Updates
NIH Halts Hydroxychloroquine Study; Says ‘Unlikely’ To Help COVID-19 Patients

Those broader considerations that the WHO is considering include the cost of remdesivir, the complexity of administering it in a medical setting, the potential risks giving it as an infusion — and weighing that against the potential benefits. Smith says the FDA, on the other hand, is looking primarily at clinical improvement from using the drug: whether patients’ symptoms improve, whether fewer people die, for example.

«This is really consistent with how we think about health care in the U.S.,» she says, «which is that we’re willing to spend a lot of money on health care for a very small improvement. And that is not the model everywhere in the world.»

• remdesivir
• COVID
• COVID-19
• treatment
• U.S.
• public health
• WHO